MACH7 TECHNOLOGIES LIMITED — Capital/Financing Update 2017

Mar 26, 2017

27 March 2017

==> picture [599 x 88] intentionally omitted <==

ASX Announcement

Release of securities from escrow

Melbourne, Australia; 27 March 2017: Mach7 Technologies Limited (the Company ) (ASX: M7T ) advises in accordance with ASX Listing Rule 3.10A that the following securities in the Company ( Restricted Securities ) will be released from escrow on 8 April 2017:

1. 44,193,300 fully paid ordinary shares; and

2. 24,047,282 performance shares, consisting of:

   • 14,428,370 Class A performance shares

   • 4,809,456 Class B performance shares

   • 4,809,456 Class D performance shares

The Restricted Securities were issued as part consideration to the vendors of the Mach7 business which the Company acquired in 2016.

The Company will seek ASX quotation of the 44,193,300 fully paid ordinary shares upon their release from escrow on 8 April 2017. The performance shares will remain unquoted following their release from escrow on 8 April 2017. Each performance share will convert into one fully paid ordinary share only upon the achievement of prescribed milestones.

- ENDS

Contacts:

Jenni Pilcher Alyn Tai CEO Australia, CFO Company Secretary +61 3 9646 2222 (Australia) +61 3 9286 7500 (Australia) jenni.pilcher@mach7t.com alyn.tai@mach7t.com

About Mach7 Technologies:

Mach7 Technologies (ASX:M7T) develops innovative enterprise imaging IT solutions that create a clear and complete view of the patient to inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. Mach7’s awardwinning enterprise imaging platform provides a vendor neutral foundation for unstructured data consolidation and communication to power interoperability and enables healthcare enterprises to build their best-of-breed clinical ecosystems. Mach7’s sophisticated workflow tools, advanced clinical viewing and optimised vendor neutral archiving solutions unlock silos of legacy systems empowering healthcare providers to own, access and share patient data without boundaries. Visit www.mach7t.com

Mach7’s wholly-owned subsidiary, 3D Medical Pty Ltd, provides medical specific 3D printing and is an exclusive distributor of various synergistic technologies including holographic projection. 3D Medical’s innovative products leverage data already captured by conventional imaging modalities and apply it in more meaningful ways to deliver improved economic and patient outcomes. Visit www.3dmedical.com.au

==> picture [612 x 123] intentionally omitted <==